OmniAb (OABI) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- -$0.12
- Estimate
- -$0.13
- Surprise
- +7.7%
- Revenue (period 2026-09-30)
- $4.0M
- Score at report (before → after)
- 5.3 → 5.5/10
Revenue source: xbrl.
How the report landed
OmniAb (OABI) reported a narrower loss than forecast — adjusted EPS of -$0.12 against the -$0.13 estimate (a 7.7% beat on a still-unprofitable quarter). TrendMatrix's engine moved from Buy (Wait) (5.3/10) to Hold at 5.5/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates OABI Hold at 5.5/10.
3 of the last 4 quarters beat the estimate; this quarter's +7.7% surprise compares with a +20.2% four-quarter average.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Strong earnings beat streak (3/4)
What argues against it
- V7 low-quality RISK_OFF penalty: -0.5 (Q=4.6)
- Value-trap signals (2/5): Margin compression (op margin -49.5%), Negative free cash flow
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $5.11
- Price target
- $7.25
- Stop
- $4.75
- Upside to target
- +41.9%
- Reward-to-risk
- 2.8:1
Risk check: trading volume is running 1.5× its average — elevated turnover around the report window.
Model outputs from TrendMatrix’s engine as of 2026-10-31 — shown for context, not personalized investment advice.
OABI at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $742.9M
- P/E (fwd)
- -17.5
- 52-week range
- $1.30–$5.43
- Off 52-week high
- 5.9%
- RSI (14)
- 58
- Volume vs avg
- 1.53×
- Score today
- 5.5/10